- Home
- TVTX vs OMAB Comparison
TVTX vs OMAB Comparison
Compare TVTX & OMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TVTX | OMAB |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | Mexico |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Aerospace |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.0B |
| IPO Year | 2013 | 2006 |
Fundamental Metrics
Financial Performance| Metric | TVTX | OMAB |
|---|---|---|
| Price | $48.93 | $109.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 7 |
| Target Price | $75.14 | ★ $116.41 |
| AVG Volume (30 Days) | ★ 2.3M | 114.1K |
| Earning Date | 11-02-2026 | 10-27-2026 |
| Dividend Yield | N/A | ★ 4.97% |
| EPS Growth | ★ 92.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $55.24 | $5.85 |
| Revenue Next Year | $43.78 | $10.81 |
| P/E Ratio | ★ N/A | $21.86 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.59 | $87.31 |
| 52 Week High | $68.73 | $134.99 |
Technical Indicators
Market Signals| Indicator | TVTX | OMAB |
|---|---|---|
| Relative Strength Index (RSI) | 47.24 | 75.24 |
| Support Level | $49.46 | $104.46 |
| Resistance Level | $59.93 | $109.12 |
| Average True Range (ATR) | 2.67 | 2.62 |
| MACD | 0.37 | 1.55 |
| Stochastic Oscillator | 76.14 | 94.90 |
Price Performance
Historical ComparisonAbout TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
About OMAB Grupo Aeroportuario del Centro Norte S.A.B. de C.V. ADS
Grupo Aeroportuario del Centro Norte SAB de CV operates, maintains and develops airports in the Mexico. The airport is in Monterrey, which serves nearly half of the company's total passengers. In addition, the company manages hotels, industrial parks, and individual airports. Its reportable segments include its airports, the Terminal 2 NH Collection Hotel, the Hilton Garden Inn Hotel and the OMA-VYNMSA Industrial Park, and in Others.